Biology of Blood and Marrow Transplantation Reach-2 Trial Design: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Compared to Best Available Therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem Cell Transplantation Gérard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Jeff Szer, Mohamad Mohty, Mary Laughlin, Betty Molloy, Leslie O'Sullivan- Djentuh, Robert Zeiser Biology of Blood and Marrow Transplantation Volume 24, Issue 3, (March 2018) DOI: 10.1016/j.bbmt.2017.12.167 Copyright © 2017 Terms and Conditions
Figure 1 Study design. Biology of Blood and Marrow Transplantation 2018 24, DOI: (10.1016/j.bbmt.2017.12.167) Copyright © 2017 Terms and Conditions